Contineum Therapeutics
CTNM
90 hedge funds and large institutions have $399M invested in Contineum Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 11 closing their positions.
100% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 11
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
18% more capital invested
Capital invested by funds: $338M → $399M (+$60.7M)
13% more funds holding
Funds holding: 80 → 90 (+10)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
34.64% less ownership
Funds ownership: 128.15% → 93.52% (-35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.45M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$7.04M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$3.83M |
| 5 |
LP
Longaeva Partners
Chicago,
Illinois
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.9M |
| 2 |
CC
Commodore Capital
New York
|
-$9.33M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.04M |
| 4 |
PA
Perceptive Advisors
New York
|
-$2.8M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.4M |
CTNM Hedge Fund Activity: Q1 2026 in Review
90 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q1 2026, worth a combined $399M — up 18% from $338M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CTNM positions and 11 closed out — a net gain of 11 holders — while 29 added to existing stakes and 21 trimmed.
The largest buyer was Millennium Management, adding an estimated $9.45M. The largest seller was RA Capital Management, cutting an estimated $11.9M.
- 90 institutional investors held Contineum Therapeutics (CTNM) as of Q1 2026, up from 80 in Q4 2025.
- Funds reported $399M of Contineum Therapeutics stock for Q1 2026, up 18% quarter-over-quarter.
- 22 funds opened new Contineum Therapeutics positions in Q1 2026 and 11 closed out, a net change of +11 holders.
- The largest Contineum Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $9.45M added.
- The largest Contineum Therapeutics seller in Q1 2026 was RA Capital Management, an estimated $11.9M sold.
Based on aggregated 13F filings for Q1 2026.